Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion
Mankind Pharma Ltd 路 Investor Presentation 路 26 Oct 2026, 8:58 pm
Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion Mankind Pharma reported Q2 FY27 revenue of INR 4,338 Cr, up 17.3% YoY, driven by a 14.8% increase in domestic business to INR 3,657 Cr and a 32.7% rise in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr as EBITDA margin expanded 210 bps to 27.1%. PAT surged 37.7% YoY to INR 716 Cr with a 16.5% margin. Net debt stood at INR 2,639 Cr (0.6x Adj. EBITDA). The company entered next-gen CAR-T therapies via an ACTx acquisition.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA 路 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference 路 06 Nov 2026
- Please find attached intimation regarding ESG Rating 路 05 Nov 2026
- Intimation of participation in the Investor Conference. 路 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 路 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL 路 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet 路 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 路 27 Oct 2026
